Opus Genetics, Inc. (IRD) stock
IRDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30459% above fair value
$4.06−0.25 (-5.80%)
Close on Nov 12, 2026Market cap $337.78MP/E –Yield –
Opus Genetics r&d expenses
Research and development expenses are spending on new products and technology.
Opus Genetics's R&D Expenses for the twelve months ending Sep 30, 2026 was $46.71M, up 70.3% year over year. For fiscal 2025 it was $30.81M, up 14.8% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $30.81M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.81M | +14.8% |
| FY2024 | Dec 31, 2024 | $26.85M | +52.1% |
| FY2023 | Dec 31, 2023 | $17.65M | +23.0% |
| FY2022 | Dec 31, 2022 | $14.36M | -5.4% |
| FY2021 | Dec 31, 2021 | $15.17M | +128.2% |
| FY2020 | Dec 31, 2020 | $6.65M | +180.2% |
| FY2019 | Dec 31, 2019 | $2.37M | -81.9% |
| FY2018 | Dec 31, 2018 | $13.11M | +22.3% |
| FY2017 | Dec 31, 2017 | $10.72M | +6.2% |
| FY2016 | Dec 31, 2016 | $10.09M | -16.9% |
| FY2015 | Dec 31, 2015 | $12.15M | +73.2% |
| FY2014 | Dec 31, 2014 | $7.02M | +115.7% |
| FY2013 | Dec 31, 2013 | $3.25M | -4.1% |
| FY2012 | Dec 31, 2012 | $3.39M | -71.7% |
| FY2011 | Dec 31, 2011 | $11.99M | +204.8% |
| FY2010 | Dec 31, 2010 | $3.93M | +23.9% |
| FY2009 | Dec 31, 2009 | $3.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $14.49M | +126.2% |
| Q2 FY2026 | Jun 30, 2026 | $11.21M | +86.1% |
| Q1 FY2026 | Mar 31, 2026 | $10.58M | +33.0% |
| Q4 FY2025 | Dec 31, 2025 | $10.43M | +48.3% |
| Q3 FY2025 | Sep 30, 2025 | $6.41M | -28.6% |
| Q2 FY2025 | Jun 30, 2025 | $6.02M | -1.1% |
| Q1 FY2025 | Mar 31, 2025 | $7.95M | +67.5% |
| Q4 FY2024 | Dec 31, 2024 | $7.03M | +83.1% |
| Q3 FY2024 | Sep 30, 2024 | $8.98M | +157.1% |
| Q2 FY2024 | Jun 30, 2024 | $6.09M | +28.9% |
| Q1 FY2024 | Mar 31, 2024 | $4.75M | -15.1% |
| Q4 FY2023 | Dec 31, 2023 | $3.84M | +7.1% |
| Q3 FY2023 | Sep 30, 2023 | $3.49M | +23.2% |
| Q2 FY2023 | Jun 30, 2023 | $4.72M | +49.4% |
| Q1 FY2023 | Mar 31, 2023 | $5.60M | +17.2% |
| Q4 FY2022 | Dec 31, 2022 | $3.59M | -24.3% |
| Q3 FY2022 | Sep 30, 2022 | $2.84M | -9.3% |
| Q2 FY2022 | Jun 30, 2022 | $3.16M | -17.4% |
| Q1 FY2022 | Mar 31, 2022 | $4.77M | +37.0% |
| Q4 FY2021 | Dec 31, 2021 | $4.74M | +9.2% |
| Q3 FY2021 | Sep 30, 2021 | $3.13M | +126.0% |
| Q2 FY2021 | Jun 30, 2021 | $3.83M | +438.5% |
| Q1 FY2021 | Mar 31, 2021 | $3.48M | +1497.2% |
| Q4 FY2020 | Dec 31, 2020 | $4.34M | +853.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.38M | +22.2% |
| Q2 FY2020 | Jun 30, 2020 | $711.00K | -56.9% |
| Q1 FY2020 | Mar 31, 2020 | $218.00K | -90.3% |
| Q4 FY2019 | Dec 31, 2019 | $454.73K | -83.3% |
| Q3 FY2019 | Sep 30, 2019 | $1.13M | -60.8% |
| Q2 FY2019 | Jun 30, 2019 | $1.65M | -52.0% |
| Q1 FY2019 | Mar 31, 2019 | $2.24M | -44.8% |
| Q4 FY2018 | Dec 31, 2018 | $2.73M | -16.4% |
| Q3 FY2018 | Sep 30, 2018 | $2.89M | +9.2% |
| Q2 FY2018 | Jun 30, 2018 | $3.43M | +34.9% |
| Q1 FY2018 | Mar 31, 2018 | $4.06M | +79.4% |
| Q4 FY2017 | Dec 31, 2017 | $3.26M | +56.5% |
| Q3 FY2017 | Sep 30, 2017 | $2.64M | – |
| Q2 FY2017 | Jun 30, 2017 | $2.54M | – |
| Q1 FY2017 | Mar 31, 2017 | $2.26M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.08M | – |
See a number that looks wrong?